Currently, numerous studies are in progress to investigate the possibility of new therapies targeting S1P signaling, including FTY720, which may have great potential as a therapeutic target for many types of diseases such as autoimmune diseases, allergy, infection, and chronic inflammation. Here, MBTPS1 is linked to allergic disease.